Table 3.

Characteristics of the clinical trials included in the review

Author, year	Total patients	Total cycles	Age years	Cause infertility	Stimulation of ovulation		Triggering treatment	Luteal phase support		Outcomes
					No	Treatment		No. intervention/control	Treatment
Agha-Hosseini, 2012 [18]	300	290	27	Unexplained infertility	38	Clomiphene citrate 50 mg/12 h for 5 days	10.000 hCG	148/142	400 mg vaginal progesterone suppositories (Cyclogest®) once daily until the 12th week	CPb, BPc, MPd, Miscarriage
					96	Letrozole 5 mg/24 h for 5 days
					66	Clomiphene citrate 5 days + hMGa 75 IU 5 days
					90	Letrozole 5 days + hMG 75 IU 5 days
Maher, 2011 [19]	71	258	30	Female (ovarian, tubal), male, combined, unexplained	258	rFSH 75 IU	10.000 hCG	132/126	90 mg vaginal progesterone gel (Crinone® 8 %) once daily for 14 days	LBe, CP, BP, MP, Miscarriage
Kyrou, 2010 [20]	468	400	32	Male, lesbian, single mother, unexplained.	400	Clomiphene citrate 50 mg	5.000 hCG	196/204	200 mg/8 h vaginal progesterone suppositories (Utrogestan®) until the 7th week	CP, BP, MP, Miscarriage
Ebrahimi, 2010 [21]	200	511	28	Unexplained infertility	511	Clomiphene citrate 50 mg/12 h for 5 days + hMG 75 IU until hCG	5.000 hCG	252/259	400 mg vaginal progesterone suppositories (Cyclogest®) once daily until the 10th week	LB, CP, BP, MP, Miscarriage
Erdem, 2009 [22]	214	427	30	Unexplained infertility	427	rFSH 75 IU	10.000 hCG	223/204	90 mg vaginal progesterone gel (Crinone® 8 %) once daily until the 12th week	LB, CP, BP, MP, Miscarriage

^a hMG human menopausal gonadotropin

^b CP clinical pregnancy

^c BP biochemical pregnancy

^d MP multiple pregnancy

^e LB live birth